This is an old revision of the document!
ACTIV-6
ACTIV-6, officially ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications, is an American study of repurposed drugs to treat COVID-19. The four drugs included in the study are ivermectin, fluvoxamine, fluticasone and montelukast.
The study officially began on June 8, 2021, and is scheduled for completion in March 2024.1)
History
The study was first posted to ClinicalTrials.gov on May 13, 2021.2)
Participants
ACTIV-6 is being led by principal investigators Susanna Naggie and Adrian Hernandez at the Duke Clinical Research Institute.
Funding
ACTIV-6 is funded by:3)
External links
1)
, 2)
Naggie, S., National Center for Advancing Translational Sciences (NCATS), & Vanderbilt University Medical Center. (2023, May 4). ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications. ClinicalTrials.gov. https://web.archive.org/web/20230518153157/https://clinicaltrials.gov/ct2/show/NCT04885530
3)
Naggie, S., Boulware, D. R., Lindsell, C. J., Stewart, T. G., Slandzicki, A. J., Lim, S. C., Cohen, J., Kavtaradze, D., Amon, A. P., Gabriel, A., Gentile, N., Felker, G. M., Jayaweera, D., McCarthy, M. W., Sulkowski, M., Rothman, R. L., Wilson, S., DeLong, A., Remaly, A., & Wilder, R. (2023). Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2023.1650